Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baltaleucel-T - CAGT/Kuur Therapeutics

Next Previous
X
Search
Drug Profile

Baltaleucel-T - CAGT/Kuur Therapeutics

Alternative Names: CMD-003; Cytorex-EBV; EBV-specific cytotoxic T-lymphocytes - CAGT/Kuur Therapeutics; EBV-specific T-cells - CAGT/Kuur Therapeutics; Epstein Barr virus antigen-activated T-cells - CAGT/Kurr Therapeutics; Epstein Barr virus-specific cytotoxic T-lymphocytes - CAGT/Kurr Therapeutics; Epstein Barr virus-specific T-cells - CAGT/Kurr Therapeutics

Latest Information Update: 11 May 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Center for Cell and Gene Therapy; Kuur Therapeutics
  • Class Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Post-transplant lymphoproliferative disorder; Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
  • No development reported Epstein-Barr virus infections

Most Recent Events

  • 04 May 2021 Kuur Therapeutics has been acquired by Athenex
  • 18 Sep 2020 Phase-II development is ongoing for Diffuse large B cell lymphoma (In adolescents, In adults, Second-line therapy or greater), Hodgkin's disease (In adolescents, In adults, Second-line therapy or greater) and Post-transplant lymphoproliferative disorder (In adolescents, In adults, Second-line therapy or greater) in USA (IV) (Kuur Therapeutics pipeline, September 2020)
  • 10 Mar 2020 Cell Medica is now called Kuur Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top